Comparison of Venlafaxine Alone Versus Venlafaxine Plus Bright Light Therapy Combination for Severe Major Depressive Disorder


Ozdemir P., Boysan M., Smolensky M. H. , Selvi Y., Aydin A., Yilmaz E.

JOURNAL OF CLINICAL PSYCHIATRY, vol.76, no.5, 2015 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 76 Issue: 5
  • Publication Date: 2015
  • Doi Number: 10.4088/jcp.14m09376
  • Journal Name: JOURNAL OF CLINICAL PSYCHIATRY
  • Journal Indexes: Science Citation Index Expanded, Social Sciences Citation Index, Scopus

Abstract

Objective: Phototherapy, ie, bright light therapy, is an effective and safe treatment of major depressive disorder (MDD). It exerts rapid mood-elevating activity, similar to antidepressant medications, most likely mediated through both monoaminergic and circadian system melatonergic mechanisms. We assessed the efficiency of bright light therapy as an adjuvant treatment to antidepressant pharmacotherapy in patients with severe MDD randomized by Hamilton Depression Rating Scale (HDRS) score to either (1) 150 mg venlafaxine hydrochloride daily at 7: 00 am or (2) 150 mg venlafaxine plus 60-minute light of 7000 lux the initial week of clinical management (venlafaxine + bright light therapy) daily at 7: 00 am.